The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part B (pembrolizumab + chemotherapy).
 
Jennifer A. Chan
Stock and Other Ownership Interests - Merck
Honoraria - Advanced Accelerator Applications; Ipsen; Lexicon
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer (I); Crinetics Pharmaceuticals; Lexicon; Pfizer (I)
Research Funding - Lilly (Inst); Sanofi (Inst)
 
Nitya Prabhakar Raj
Research Funding - Novartis (Inst); Xencor (Inst)
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Axiom Biotechnologies; Clovis Oncology; Dendreon
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BioXCel therapeutics (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
 
Susan Calabrese
No Relationships to Disclose
 
April DeMore
No Relationships to Disclose
 
Mallika Sachdev Dhawan
No Relationships to Disclose
 
Delaire Fattah
No Relationships to Disclose
 
Lawrence Fong
Stock and Other Ownership Interests - Alector; Alector; Atreca; BioAtla; Bolt Biotherapeutics; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; TeneoBio; TeneoBio
Consulting or Advisory Role - Alector; AstraZeneca; Atreca; BioAtla; Bolt Biotherapeutics; Bristol-Myers Squibb; Dendreon; EMD Serono; Janssen Oncology; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; TeneoBio
Research Funding - Abbvie (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Jennifer Grabowsky
No Relationships to Disclose
 
Thomas A Hope
Honoraria - GE Healthcare
Consulting or Advisory Role - Curium Pharma; Ipsen
Research Funding - Advanced Accelerator Applications (Inst); GE Healthcare; Philips Healthcare
Travel, Accommodations, Expenses - GE Healthcare
 
Kanti Pallav Kolli
Stock and Other Ownership Interests - Adient Medical
Travel, Accommodations, Expenses - AngioDynamics; inari medical
 
Pamela N. Munster
Leadership - Alessa Therapeutics; EpiAxis Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics; AtlasMedx; OnKure
Honoraria - CStone Pharmaceuticals; Epigene; Prometheus (I)
Consulting or Advisory Role - Array BioPharma (I); AstraZeneca; Athenex; AtlasMedx; BeiGene; BMSi (I); GenomeSmart; IQvia (I); Jubilant Pharmaceuticals; NeoHealth (I); RasCal; RasCal
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents
 
Kimberly Perez
Consulting or Advisory Role - Celgene; Eisai
 
Diane Lauren Reidy
Honoraria - Novartis
Consulting or Advisory Role - Advanced Accelerator Applications; Lexicon
Research Funding - Ipsen; Merck; Novartis
 
Sofia Von Fedak
No Relationships to Disclose
 
Li Zhang
Consulting or Advisory Role - Dendreon; Fortis; Unity Biotechnology
Travel, Accommodations, Expenses - Dendreon; Dendreon; Dendreon
 
Emily K. Bergsland
Leadership - More Health (I)
Stock and Other Ownership Interests - More Health (I)
Honoraria - UpToDate
Consulting or Advisory Role - Advanced Accelerator Applications; Crinetics Pharmaceuticals; Hutchison MediPharma; more health (I)
Research Funding - Merck; Novartis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Travel, Accommodations, Expenses - Crinetics Pharmaceuticals